Bioequivalence test of two drugs in healthy adults
Official title: An Open-lable, Randomized, Fasting, Single-dose, Oral Administration, 2-sequence, 4-period, Replicate Crossover Study to Evaluate Bioequivalence Between YHP2508A and YHR2601 in Healthy Subjects
Run by Yuhan Corporation · NCT07912827 · Data updated 2026-11-12
This study tests whether YHP2508A and YHR2601 are bioequivalent in healthy volunteers.
Quick facts
| Phase | Phase 1 |
|---|---|
| Study type | Interventional |
| Ages | 19 Years to 54 Years |
| Sex | All |
| Enrollment | 44 (estimated) |
| Sponsor | Yuhan Corporation Industry-sponsored |
| Locations | 2 sites (Seoul and 1 other locations) |
| Status | Recruiting |
| Started | October 20, 2026 |
| Main results expected | February 2, 2027 |
| Study ends | February 2, 2027 |
| Registry record updated | November 3, 2026 |
| Trial ID | NCT07912827 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Healthy adults aged generally within BMI 18-30 kg/m2 without significant diseases.
✕Probably not a fit
Individuals with undisclosed chronic conditions or those who do not meet the eligibility criteria may not benefit.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This is a Phase 1, open-label, randomized, fasting, single-dose, oral crossover study in healthy adults. Participants are assigned to two groups and receive both drugs in different sequences across four periods to compare how the body processes each drug. The trial uses two 2-sequence, 4-period replicate crossover designs to determine bioequivalence. About 44 healthy subjects will be enrolled to ensure reliable comparison. The study aims to determine if the two formulations behave similarly in pharmacokinetics.
Why it matters
Potential benefit: If successful, patients could have access to equivalent therapeutic options with similar pharmacokinetic profiles.
How similar studies have gone: Bioequivalence studies using replicated crossover designs are commonly used to compare formulations and have shown success in similar settings.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * BMI 18-30 kg/m2 * Those without clinically significant congenital or chronic diseases Exclusion Criteria: * Those who have participated in a bioequivalence study or other clinical trials and have been administered investigational products within 6 months prior to the first administration * Those who are judged ineligible to participate in the trial by the principal investigator * Female volunteers who are pregnant, suspected to be pregnant or breathfeeding
Where it's running
-
H+ Yangji Hospital
Seoul, South Korea Recruiting -
H+ Yangji Hospital
Seoul, South Korea Recruiting
Study contacts
- Study coordinator: Jungwook Lee, MS
- Email: clinicaltrials@yuhan.co.kr
- Phone: 82-2-828-0504
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Bioequivalence comparison between YHP2508B and YHR2602 in healthy adults
This study tests whether YHP2508B and YHR2602 deliver similar amounts of the drug in healthy adults after a single dose.
-
Reactive Balance Training with Augmented Reality for Older Adults
This study tests whether reactive balance training using augmented reality helps older adults who are at risk of falling, compared with regular treadmill walking.
-
How the body responds to exercise with low oxygen in healthy adults
Researchers test how healthy men and women respond to different exercise types while breathing air with varying oxygen levels.
-
IS M8969 safety and PK/PD in healthy and at-risk adults
This early-phase study tests ISM8969 versus placebo to see if it is safe, well tolerated, and how the body handles and responds to it in healthy adults and obese adults at risk for heart disease.
-
Ear-based vagus nerve stimulation to improve reaction time
Researchers will try a short, noninvasive electrical stimulation of the vagus nerve at the ear to see if it shortens reaction time in healthy adults.
-
Single ascending-dose safety and response test of SYH2070 injection in healthy adults
This test gives a single subcutaneous dose of SYH2070 to healthy adults with mildly high triglycerides to see whether it is safe, how the body handles it, and whether it causes early biological effects compared with placebo.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.